Available: http://www.bbmt.org/article/S1083-8791(08)00245-0/pdf Abstract: Recovery of gonadal function in patients after allogeneic stem cell transplantation for hematologic malignancies is uncommon, and only a few cases have been reported. We report the case of a 39-year-old woman who had a normal full-term delivery 8 years after allogeneic bone marrow transplantation for chronic myeloid leukemia. Conditioning consisted of cyclophosphamide 120 mg/kg over 2 days and Busulfan 16 mg/kg over 4 days (BuCy). To our knowledge, this is the second reported case of pregnancy after BuCy conditioning. Abstract:Patients successfully treated with a marrow transplant often have concerns about fertility and pregnancy. This study was performed to determine pregnancy outcome among patients who had received high-dose chemotherapy alone or with total-body irradiation (TBI) and marrow transplantation for aplastic anemia or hematologic malignancy. Records of 1,326 postpubertal and 196 prepubertal patients currently more than 12 years of age after marrow transplant in Seattle from August 1971 to January 1992 were reviewed to determine the patients with normal gonadal function and pregnancies. Among 708 postpubertal women, 110 recovered normal ovarian function and 32 became pregnant. In addition, nine formerly prepubertal girls with normal gonadal function became pregnant. Among 618 postpubertal men, 157 recovered testicular function and partners of 33 became pregnant. An additional two formerly prepubertal men had partners who became pregnant. Forty-one female patients and partners of 35 male patients had 146 pregnancies after transplant. All 76 patients responded to a questionnaire requesting pregnancy history, outcome, infant birth weight, and congenital anomalies information for all clinically recognized pregnancies. There were 115 live births among 146 (79%) pregnancies. Spontaneous abortion terminated four of 56 (7%) pregnancies for 28 female cyclophosphamide (CY) recipients and six of 16 (37%) pregnancies for 13 TBI recipients (P = .02). Partners of 28 male CY recipients had four of 62 (6.4%) pregnancies terminate with spontaneous abortion, but there were no spontaneous abortions among eight pregnancies of five TBI recipients' partners. Preterm delivery occurred for eight of 44 (18%) and five of eight (63%) live births for 24 CY and eight TBI female recipients (P = .01). This 25% incidence among all female patient pregnancies is higher than the expected incidence of 8% to 10% (P = .0001). The 13 preterm deliveries resulted in 10 low birth weight ([LBW] 1.8 to 2.24 kg) and three very low birth weight ([VLBW] <1.36 kg) infants, for an overall incidence of 25%, which is higher than the expected incidence of 6.5% for the general population (P = .0001). Twelve of the 13 premature infants survive. Congenital anomalies were seen among two of 52 (3.8%) live-born infants of female and six of 63 (9.5%) live-born infants of male patients, which is not different from the 13% of single congenital anomalies reported for the general population. These data demonstrate that clinically recognized pregnancies among women who have received a marrow transplant incorporating TBI are likely to be accompanied by an increased risk of spontaneous abortion. Pregnancies among all women who received a marrow transplant are likely to be accompanied by preterm labor and delivery of LBW or VLBW babies who do not seem to be at an increased risk of congenital anomalies. However, determination of possible adverse effects of parental exposure to high-dose alkylating agents with or without TBI on children born posttransplant requires longer, additional follow-up.
Abstract:We report a rare case of a 23 year-old female who had ovarian function recovery and a normal full term delivery after hormone-replacement therapy (HRT) through 9 years after allogeneic HSCT with busulphan-based conditioning regimen for AML. The conditioning regimen consisted of busulfan 16 mg/kg, cyclophosphamide 120 mg/kg, and Liposomal daunorubicin 200 mg/m2. Successful engraftment of donor cells and full donor's chimerism was achieved without signs of leukemia. One year after the HSCT the patient received a course of HRT as a treatment of hypergonadotropic hypogonadism and absence of menses. After 12 months of the HRT recovery of ovarian function was confirmed. Eight years after the HSCT spontaneous pregnancy occurred; heartbeat of the fetus was registered on week 7. Three weeks later a non-severe vaginal bleeding occurred and ultrasound examination showed a non-developing pregnancy. Genetic examination of the abortion material revealed a full triploid genotype (69 XXX). After 4 months spontaneous pregnancy occured again. At 20 weeks of gestation woman was advised by geneticist. According to the results of studies of genetic markers, the genetic risk of fetal chromosomal pathology is regarding as low. All clinical and laboratory parameters were within normal limits. The whole period of pregnancy was uneventful. At 37-38 weeks' gestation the patient was admitted to the hospital with preterm premature rupture of membranes. Considering this, as well as signs of chronic fetal hypoxia, Cesarean section was performed. A girl infant was delivered with a birth weight of 3492g and Apgar scores of 4 and 7 at 1 and 5min, respectively. Postpartum period was unremarkable. On the 6th day the mother and newborn were discharge in satisfactory condition. To our knowledge this is a first case of ovarian function restoration and spontaneous pregnancy in a AML patient after multiple courses of high dose chemotherapy and allogeneic transplant with busulphan-based myeloablative conditioning. The effect of many contemporary chemotherapeutic drugs on pregnancy and livebirth is not well established. We aimed to establish the effects of these drugs on pregnancy in male and female survivors of childhood cancer not exposed to pelvic or cranial radiotherapy. Methods: We used data from a subset of the Childhood Cancer Survivor Study cohort, which followed 5-year survivors of the most common types of childhood cancer who were diagnosed before age 21 years and treated at 27 institutions in the USA and Canada between 1970 and 1999. We extracted doses of 14 alkylating and similar DNA interstrand crosslinking drugs from medical records. We used sex-specific Cox models to establish the independent effects of each drug and the cumulative cyclophosphamide equivalent dose of all drugs in relation to pregnancies and livebirths occurring between ages 15 years and 44 years. We included siblings of survivors as a comparison group. Findings: We included 10 938 survivors and 3949 siblings. After a median follow-up of 8 years (IQR 4-12) from cohort entry or at age 15 years, whichever was later, 4149 (38%) survivors reported having or siring a pregnancy, of whom 3453 (83%) individuals reported at least one livebirth. After a median follow-up of 10 years (IQR 6-15), 2445 (62%) siblings reported having or siring a pregnancy, of whom 2201 (90%) individuals reported at least one livebirth. In multivariable analysis, survivors had a decreased likelihood of siring or having a pregnancy versus siblings (male survivors: hazard ratio [HR] 0.63, 95% CI 0.58-0.68; p2 increments: HR 0.82, 95% CI 0.79-0.86; p2 HR 0.22, 95% CI 0.06-0.79; p=0.020; >450 mg/m2 0.14, 0.03-0.55; p=0.0051) and doses of lomustine equal to or greater than 411 mg/m2 (0.41, 0.17-0.98; p=0.046) were significantly associated with reduced pregnancy; cyclophosphamide equivalent dose was associated with risk only at the highest doses in analyses categorised by quartile (upper quartile vs no exposure: HR 0.85, 95% CI 0.74-0.98; p=0.023). Results for livebirth were similar to those for pregnancy. Interpretation: Greater doses of contemporary alkylating drugs and cisplatin were associated with a decreased likelihood of siring a pregnancy in male survivors of childhood cancer. However, our findings should provide reassurance to most female survivors treated with chemotherapy without radiotherapy to the pelvis or brain, given that chemotherapy-specific effects on pregnancy were generally few. Nevertheless, consideration of fertility preservation before cancer treatment remains important to maximise the reproductive potential of all adolescents newly diagnosed with cancer. Abstract:Hematopoietic stem cell transplantation (HCT) is a standard treatment for young patients with Severe Aplastic Anemia and an available matched sibling donor. Conditioning regimens frequently use high-dose cyclophosphamide. A second conditioning agent is frequently associated when transplanting patients with multiple prior transfusions to decrease the risk of primary or secondary graft failure. Low dose oral Busulfan has been used in our country for many years, but the impact of this therapy on fertility has never been evaluated. The objective of this study is to retrospectively evaluate fertility in patients with Severe Aplastic Anemia who underwent allogeneic HCT with Busulfan 4 mg/Kg and Cyclophosphamide 200 mg/Kg. Methods: Retrospective chart review. Patients without appropriate information in the hospital charts were called, asked about pregnancy, and scheduled a regular appointment at the HCT service. All patients had related allogeneic bone marrow grafts from matched sibling donors, received the same conditioning therapy, and GVHD prophylaxis based on Cyclosporine and Methotrexate. Results: A total of 29 consecutive patients underwent HCT between 1991 and 2014, were alive, and had the information on fertility. The patients had a median age of 22 years at the time of transplant (range 6-36) and were followed after transplant for 2 to 24 years (median 14 years). Twenty-two were male and seven were female. Among the 7 females, 3 had documented ovarian failure; other 3 have tried to become pregnant and all of them did, having 2 normal children and 2 abortions. The patients reported no congenital anomaly. Twenty-two men were contacted: 12 had testosterone levels drawn, and it was low in only one man. Among the 12/22 men who wanted to make their wives pregnant, only one was not successful. The 11 male patients fathered 19 children (between 1 and 3 children per male patient). Conclusions: Very low dose Busulfan associated to Cyclophosphamide seems to have an important adverse impact on ovarian function: half of the females developed gonadal failure, while only one out of 22 men had low testosterone levels. In patients with normal gonadal function, pregnancy seems to be normal with 21 normal babies being born from 2/3 females and 11/ 12 man after the transplant. Since the relatively high rate of gonadal failure in females may be also secondary to high dose Cyclophosphamide, novel conditioning regimens are still desired for women with Severe Aplastic Anemia who still have the desire to get pregnant. (Table Presented) . 1-19) . At the time of the study a meanGS.D. of 13G5.5 years (range 6-27) had elapsed since the HSCT and the mean age of the participants was 22G6.3 years (range 9-41). Results: Spontaneous puberty based on breast development occurred in 40 and menarche in 30 of the 70 girls who were prepubertal at transplantation. Six out of 20 girls who received HSCTafter initiation of pubertal development recovered their ovarian function. Younger age at HSCT, conditioning without total body irradiation (TBI), and a non-leukemia diagnosis predicted the spontaneous menarche. The incidence of menarche was higher after fractioned vs single fraction TBI (P!0.05), cyclophosphamide (Cy) vs busulfan (Bu)-based conditioning (P!0.05), and among leukemia patients transplanted at first remission vs later remissions (P!0.01) and with no cranial irradiation (cranial radiotherapy, CRT) vs given CRT (14-24 Gy) (P!0.01). The majority of recipients conditioned with only Cy vs TBI (P!0.001) or vs Bu-based regimens (P!0.01) showed preserved ovarian function and required no estrogen replacement at their latest follow-up visit at a mean age of 23G6.3 years (range 15-41). Ten women became pregnant. Conclusions: Patients conditioned with TBI or Bu-based regimes are at high risk of ovarian failure. Intensive antileukemia therapy before HSCT including CRT especially among relapsed patients may further decrease the possibility of spontaneous menarche. © 2014 European Society of Endocrinology Printed in Great Britain.
